-
平臺(tái)編號(hào)：bio-68974
-
國(guó)際編號(hào)：HB-8555?
-
細(xì)胞信息： 2A3A1H
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
2A3A1H
細(xì)胞形態(tài)：淋巴樣
免疫類(lèi)型：IgG1
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
ATCC Number：HB-8555?
規(guī)格：0.5mg Designations: 2A3A1H
Depositors: ?Immunex Corporation
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human interleukin 2 (interleukin-2, IL-2) receptor
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with phytohemagglutinin activated human peripheral blood (PBL) leukocytes.
Spleen cells were fused with NS-1 myeloma cells.
The antibody binds to IL-2 receptors on human leukocytes and blocks both mitogen induced and antigen induced PBL proliferation.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.025 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 6 X 10 exp5 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
References: 3994: March CJ, et al. Hybridoma antibody which binds IL-2 receptor. US Patent 4,845,198 dated Jul 4 1989
3995: March CJ, et al. Interleukin-2 receptor. US Patent 4,578,335 dated Mar 25 1986
免疫類(lèi)型：IgG1
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
ATCC Number：HB-8555?
規(guī)格：0.5mg Designations: 2A3A1H
Depositors: ?Immunex Corporation
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human interleukin 2 (interleukin-2, IL-2) receptor
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with phytohemagglutinin activated human peripheral blood (PBL) leukocytes.
Spleen cells were fused with NS-1 myeloma cells.
The antibody binds to IL-2 receptors on human leukocytes and blocks both mitogen induced and antigen induced PBL proliferation.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.025 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 6 X 10 exp5 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
References: 3994: March CJ, et al. Hybridoma antibody which binds IL-2 receptor. US Patent 4,845,198 dated Jul 4 1989
3995: March CJ, et al. Interleukin-2 receptor. US Patent 4,578,335 dated Mar 25 1986
